stocks logo

FATE

Fate Therapeutics Inc
$
1.240
-0.01(-0.800%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.270
Open
1.260
VWAP
1.23
Vol
982.01K
Mkt Cap
142.14M
Low
1.190
Amount
1.21M
EV/EBITDA(TTM)
--
Total Shares
113.83M
EV
-98.28M
EV/OCF(TTM)
--
P/S(TTM)
10.96
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.33M
-28.66%
-0.308
-30.04%
1.15M
-62.63%
-0.326
-18.61%
1.14M
-83.17%
-0.344
+4.32%
Estimates Revision
The market is revising Upward the revenue expectations for Fate Therapeutics, Inc. (FATE) for FY2025, with the revenue forecasts being adjusted by 9.39% over the past three months. During the same period, the stock price has changed by -0.80%.
Revenue Estimates for FY2025
Revise Upward
up Image
+9.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.58%
In Past 3 Month
Stock Price
Go Down
down Image
-0.80%
In Past 3 Month
10 Analyst Rating
up Image
294.35% Upside
Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is 4.89 USD with a low forecast of 2.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
8 Hold
0 Sell
Hold
up Image
294.35% Upside
Current: 1.240
sliders
Low
2.00
Averages
4.89
High
12.00
Barclays
Overweight
to
NULL
downgrade
$10 -> $2
2025-05-14
Reason
Baird
Neutral
downgrade
$5 -> $4
2025-05-14
Reason
Baird lowered the firm's price target on Fate Therapeutics to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.
Needham
Gil Blum
Hold
Reiterates
n/a
2025-03-06
Reason
Wells Fargo
Yanan Zhu
Hold
Maintains
$5 → $4
2025-03-06
Reason
Wells Fargo lowered the firm's price target on Fate Therapeutics to $4 from $5 and keeps an Equal Weight rating on the shares. The firm continues to think Fate's main opportunity is in autoimmune diseases, and awaits visibility for next data readout from FT819's SLE study. Wells also highlights the recent protocol amendment to include additional autoimmune indications as interesting development.
Wedbush
David Nierengarten
Hold
Reiterates
$5
2025-03-06
Reason
Stifel
Benjamin Burnett
Hold
Maintains
$5 → $3
2025-03-06
Reason
Stifel lowered the firm's price target on Fate Therapeutics to $3 from $5 and keeps a Hold rating on the shares. Key updates the firm will be tracking throughout 2025 include FT819 data and FT825 in solid tumors, notes the analyst, whose updated model now only includes FT819 in moderate-to-severe systemic lupus erythematosus.

Valuation Metrics

The current forward P/E ratio for Fate Therapeutics Inc (FATE.O) is -0.98, compared to its 5-year average forward P/E of -12.33. For a more detailed relative valuation and DCF analysis to assess Fate Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.33
Current PE
-0.98
Overvalued PE
2.22
Undervalued PE
-26.88

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.68
Current EV/EBITDA
0.06
Overvalued EV/EBITDA
4.13
Undervalued EV/EBITDA
-19.50

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
88.97
Current PS
30.72
Overvalued PS
163.51
Undervalued PS
14.44

Financials

Annual
Quarterly
FY2025Q1
YoY :
-15.38%
1.63M
Total Revenue
FY2025Q1
YoY :
-19.17%
-41.28M
Operating Profit
FY2025Q1
YoY :
-21.63%
-37.62M
Net Income after Tax
FY2025Q1
YoY :
-31.91%
-0.32
EPS - Diluted
FY2025Q1
YoY :
+4.69%
-35.01M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-56.50%
-938.68
FCF Margin - %
FY2025Q1
YoY :
-7.39%
-2.31K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
605.4K
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
668.6K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
671.1K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
50.9K
Volume
Months
6-9
3
4.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

FATE News & Events

Events Timeline

2025-06-11 (ET)
2025-06-11
09:08:08
Fate Therapeutics announces updated data for FT819
select
2025-05-13 (ET)
2025-05-13
16:09:46
Fate Therapeutics reports Q1 EPS (32c), consensus (38c)
select
2025-04-14 (ET)
2025-04-14
08:03:51
Fate Therapeutics receives RMAT designation from FDA for FT819
select
Sign Up For More Events

News

5.0
05-30NASDAQ.COM
Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down
5.0
05-30Newsfilter
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
9.0
05-28Newsfilter
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Sign Up For More News

FAQ

arrow icon

What is Fate Therapeutics Inc (FATE) stock price today?

The current price of FATE is 1.24 USD — it has decreased -0.8 % in the last trading day.

arrow icon

What is Fate Therapeutics Inc (FATE)'s business?

arrow icon

What is the price predicton of FATE Stock?

arrow icon

What is Fate Therapeutics Inc (FATE)'s revenue for the last quarter?

arrow icon

What is Fate Therapeutics Inc (FATE)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Fate Therapeutics Inc (FATE)'s fundamentals?

arrow icon

How many employees does Fate Therapeutics Inc (FATE). have?

arrow icon

What is Fate Therapeutics Inc (FATE) market cap?